Why This Biotech Fund Increased Its Oruka Stake Amid a 500% Rally
A biotech fund just boosted its Oruka Therapeutics position after a blistering rally. Here’s what the move signals ab...
This comparison highlights essential contrasts between Zero Based and Incremental budgeting, focusing on allocation, rigor, and outcomes.
17,319 articlesA biotech fund just boosted its Oruka Therapeutics position after a blistering rally. Here’s what the move signals ab...
The CLARITY Act fight over crypto ethics stalled as lawmakers clashed on enforcement and state powers, leaving invest...
TIAA's leader recalls starting with a modest $26,000 salary and still maxing out her 401(k), underscoring the long-te...
As Meta Platforms weighs renting out idle AI compute, investors ask if the company overbuilt. This piece breaks down ...
Investors are eyeing Vera Bradley's 2026 path as it rhythms through product launches, wholesale relationships, and di...
Palantir connects data, software, and decision-making in a way that could reshape enterprise AI. This guide outlines ...
Serve Robotics has faced a meaningful pullback, but a closer look at its partnerships, deployment plans, and unit eco...
As earnings season rolls in, KTCC’s tronic 2026 earnings story becomes a focal point for value seekers. This guide br...
This article dives into EverCommerce (evcm) 2026 earnings, unpacking Q1 results, growth drivers, and the implications...
Analysts tout gains for an overlooked tech name, but the upside may be clouded by rising costs, competition, and macr...
As robotaxi plans advance, Tesla stock faces a critical test. This article explains why tesla stock gets wall Street ...
AI agents are changing how software works for businesses. This piece explains why platforms like ServiceNow and Palan...